Heart Valve Disease Policy Task Force

The Heart Valve Disease Policy Task Force is a coalition of organizations advocating for policy solutions that improve access, research, and awareness on heart valve disease detection and treatment.

To learn more about the Task Force and to join, contact Lindsay Clarke at [email protected]

Latest Issues

TAVR National Coverage Determination

On June 27th, 2018 the Centers for Medicare and Medicaid (CMS) announced that they are reconsidering the National Coverage Determination (NCD) for transcatheter aortic valve replacement (TAVR).  The current NCD lays out requirements for TAVR procedures used for the treatment of symptomatic aortic stenosis according to an FDA-approved indication.  Reopening the NCD means that CMS is reexamining how TAVR will be covered and reimbursed moving forward.  The new determination could impact access to TAVR—potentially widening or limiting the ability of patients to get TAVR.

Visit the Task Force NCD page to learn more about our advocacy priorities for the NCD and to access education and outreach materials.

Shared-Decision Making

The Heart Valve Disease Policy Task Force recognizes the value of shared decision-making and is invested in advancing models that achieve high-quality shared decision-making. A recent letter to CMS Administrator Seema Verma and CMS Director of the Center for Clinical Standards & Quality, Kate Goodrich, was signed by 42 organizations including some Task Force members. The letter urged CMS to establish clear guidance implementing the program to facilitate shared decision-making that is called for in statute. Read the letter here.

The Task Force is supported by educational support from Edwards Lifesciences.